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Abstract
The adenosine monophosphate activated kinase protein (AMPK) is an evolutionary-conserved protein important for cell
survival and organismal longevity through the modulation of energy homeostasis. Several studies suggested that AMPK
activation may improve energy metabolism and protein clearance in the brains of patients with vascular injury or
neurodegenerative disease. However, in Huntington’s disease (HD), AMPKmay be activated in the striatum of HDmice at a late,
post-symptomatic phase of the disease, and high-dose regiments of the AMPK activator 5-aminoimidazole-4-carboxamide
ribonucleotide may worsen neuropathological and behavioural phenotypes. Here, we revisited the role of AMPK in HD using
models that recapitulate the early features of the disease, including Caenorhabditis elegans neuron dysfunction before cell death
and mouse striatal cell vulnerability. Genetic and pharmacological manipulation of aak-2/AMPKα shows that AMPK activation
protectsC. elegansneurons from thedysfunction inducedbyhumanexon-1huntingtin (Htt) expression, in a daf-16/forkheadbox
O-dependent manner. Similarly, AMPK activation using genetic manipulation and low-dose metformin treatment protects
mouse striatal cells expressing full-length mutant Htt (mHtt), counteracting their vulnerability to stress, with reduction of
soluble mHtt levels by metformin and compensation of cytotoxicity by AMPKα1. Furthermore, AMPK protection is active in the
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mouse brain as delivery of gain-of-function AMPK-γ1 to mouse striata slows down the neurodegenerative effects of mHtt.
Collectively, these data highlight the importance of considering the dynamic of HD for assessing the therapeutic potential of
stress-response targets in the disease. We postulate that AMPK activation is a compensatory response and valid approach for
protecting dysfunctional and vulnerable neurons in HD.
Introduction
Adenosine monophosphate activated kinase protein (AMPK) is an
obligate heterotrimeric enzyme that is composed of AMPKα (cata-
lytic core), AMPKβ andAMPKγ (regulatoryunits). AMPK is central to
the regulation of energy homeostasis and phosphorylates a wide
range of proteins, in response to metabolic changes, mostly ATP
ﬂuctuations, through allosteric binding of AMP or ADP to AMPKγ
and/or phosphorylation of the α-subunit. After activation, AMPK
phosphorylates a range of targets to inhibit catabolic pathways
and to activate anabolic pathways to restore ATP homeostasis
(1,2). However, AMPK is also able to respond by phosphorylation
of different targets to a range of stress conditions to restore
homeostatic balance of energy levels. For instance, AMPK can pro-
mote initiation of autophagy (2,3) through inhibition of mamma-
lian target of rapamycin (mTOR) (4) or via phosphorylation of the
forkhead box O 3a (FOXO3a) (5) under conditions of low levels of
ATP or stress of different kinds.
The transcription factor FOXO, a member of the FOX (fork-
head box) family of proteins, has different isoforms inmammals,
although only one gene represents this family in Caenorhabditis
elegans, daf-16. This protein is a downstream player of the insulin
signalling pathway in C. elegans andmammals and awell-known
master regulator of lifespan that interplays upstream and down-
stream to the AMPK function across living organisms. AMPK also
operates in cross-talk with othermembers of the AMPK-like fam-
ily. For instance, the liver kinase B1 (LKB1) is a primary upstream
kinase of AMPK and it regulates polarity and also is a tumour sup-
pressor (reviewed in 6). Moreover, LKB1 is the kinase responsible
for AMPK phosphorylation in response to the drugmetformin (7).
Aside from the interaction withmTOR and FOXO3a, AMPK is able
to regulate several physiological events in cells, by signalling
through a large number of downstream targets. For instance,
AMPK can activate PGC-1α, through the modulation of NAD+/
NADH ratios and subsequent activation of sirtuin 1 (SIRT1),
which in turn induces mitochondrial biogenesis (reviewed in 8).
AMPK can also phosphorylate Unc-51 like autophagy activating
kinase 1 to promote mitophagy (9). In addition to modulating en-
ergy levels and stress response, AMPK is able to respond to a range
of drugs. For examplemetformin, an indirect AMPK activator (10),
is a widely prescribed drug to patients with type II diabetes and
has positive effects to prevent conditions such as cancer (re-
viewed in 11) or kidney disease (reviewed in 12). As indicated by
studies in C. elegans, where AMPKα, the catalytic core of AMPK,
is encoded byaak-1 and aak-2, aak-2/AMPKα is involved in lifespan
extension (13–15). On thewhole, AMPK is considered to be amas-
ter regulator of healthspan (2,16–18) and lifespan (13–15).
In the brain, AMPK activation may have several protective ef-
fects against anxiety-like behaviour (19) and ischaemia (20,21),
which may involve activation of autophagy. In Alzheimer’s dis-
ease (AD), the situation is controversial. While AMPK has been
shown to alleviate phenotypes associated with AD by reducing
oxidative stress, slowing-down the formation of amyloid plaques
and promoting the removal of β-amyloid peptides by autophagy
(15,22,23), other reports have suggested that it is AMPK inhibition
that may be protective (24), suggesting a complex picture in
which gender effects may be involved as activation of AMPK
may increase memory dysfunction in male AD mice, but may
be protective in female AD mice (25). In Huntington’s disease
(HD), metformin, an antiglycemic drug and a well-known AMPK
activator, may protect from the disease in a transgenic mouse
model (R6/2) of HD (26), suggesting that AMPK activation has
neuroprotective effects with therapeutic potential in HD. How-
ever, Ju et al. (27) have suggested that AMPK may be activated in
the striatum of HD mice at a late stage of the disease and that
chronic exposure to high-dose regiments of the AMPK activator
5-aminoimidazole-4-carboxamide ribonucleotide may worsen
neuropathological and behavioural phenotypes. Ju et al. also sug-
gested that AMPK may work downstream of oxidative stress to
mediate neuronal atrophy in HD (28).
Here, we hypothesized that AMPK activationmay be primarily
protective during the early phases of the pathogenic process in
HD, before cell death and during the early phases of neuronal de-
cline (neuronal dysfunction without advanced degeneration).
Using a C. elegans model of neuronal dysfunction in HD (29), we
observed that metformin strongly reduces neuronal dysfunction
caused by polyQ-expanded human exon-1 huntingtin (Htt) at the
young adult stage. We also show that ablation of aak-2/AMPKα
aggravates neuronal dysfunction in these animals in a cell au-
tonomous and daf-16/FOXO-dependent manner. Genetic and
chemical manipulation of AMPK in striatal cells derived from
the HdhQ111 knock-in mouse model of HD (30) recapitulates
the observations in polyQ nematodes. Furthermore, overexpres-
sing AMPK counteracted the induction of neurodegeneration by
lentivirus-mediated mutant Htt (mHtt) expression in mice stri-
ata, providing a proof-of-concept that AMPK can protect from
mHtt cytotoxicity in the context of a living brain. Collectively,
our data reveal that AMPK activation, which has anti-ageing
effects in normal conditions, also has neuroprotective effects
as the pathogenic process develops in HD, providing a rationale
for further evaluation of small molecule activators of AMPK in
the disease.
Results
aak-2/AMPK is protective in a C. elegans model
of neuronal dysfunction in HD
The function of AMPK has been linked to lifespan and health
span increase in nematodes and mice (13,31–33). Hence, we
sought to test whether this enzyme may allow neurons to com-
pensate for the stress and dysfunction that may be produced by
mHtt expression during the early phases of HD pathology. To this
end, we introduced a loss-of-function (LOF) allele of aak-2, namely
aak-2(ok524), one of the two worm homologues of AMPKα1 (13)
into a nematode model of neuronal dysfunction in HD. While
we initially attempt to do the cross in nematodes with stable
co-expression of human exon-1 Htt and YFP (29), doublemutants
could not be isolated likely because the Htt transgene is inserted
near to the aak-2 locus. We, then, turned to single-transgenic an-
imals. These animals bear a transgene that expresses the ﬁrst
exon of human Htt, with expanded (128Q) or normal (19Q) poly-
glutamines (polyQ) fused to green ﬂuorescent protein (GFP) in
touch receptor neurons (34). In 128Q nematodes, response to
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light touch is strongly impaired compared with19Q nematodes
(34) (Fig. 1A). The aak-2 LOF further reduces touch response in
128Q animals without affecting touch response in 19Q animals
(Fig. 1A). This effect was unrelatedwith a change of transgene ex-
pression (Supplementary Material, Fig. S1). This indicated that
aak-2 has neuroprotective effects in 128Q nematodes.
Next, we sought to examine whether AMPK activators might
be protective in 128Q nematodes. It has been suggested thatmet-
formin partially inhibits complex I of the mitochondrial electron
transport chain, which in turns increases the ADP/ATP ratio and
activates AMPK (35). Here, we tested whether metformin might
be able to ameliorate touch response impairment in 128Q nema-
todes. Metformin treatment at low doses (2 m in the media,
which may translate in a concentration that is 100 times less
in the animals than in the media) strongly enhanced touch re-
sponse of 128Q animals with no effect detected in 19Q animals
(Fig. 1B). Additionally, compared with 128Q nematodes, 128Q;
aak-2(ok524) nematodes show a loss of response to the positive
effect of metformin treatment (Fig. 1C), suggesting that metfor-
min protection is mostly dependent on aak-2/AMPK and may
engage AMPKα activation.
aak-2/AMPK protects 128Q nematode neurons in a cell
autonomous and daf-16/FOXO manner
We previously showed that DAF-16/FOXO, a master regulator of
lifespan andhealthspan in several organisms includingC. elegans
and mammals, has strong protective effects in C. elegans and
mammalian-cell models of HD pathogenesis (29,36,37). Interest-
ingly, FOXO factors are well-described effectors of AMPK under
conditions of fasting, to promote lifespan extension in nema-
todes (38). Other studies have shown that both aak-2 and daf-16
are downstream in-parallel effectors in regulating lifespan
through insulin signalling (31), suggesting that the AMPK-FOXO
pathway may have a complex signalling loop. Given this, we
sought to investigate whether the neuroprotection exerted by
aak-2/AMPK in 128Q nematode neurons may be dependent on
daf-16/FOXO. To this end, we crossed exon-1 Htt nematodes to a
daf-16 LOF mutant, daf-16(mu86). The daf-16 LOF strongly aggra-
vated (50%) the loss of touch response in 128Q nematodes
(Fig. 2), as expected and previously reported (36). Touch response
in 128Q;daf-16 nematodes is comparable to that of 128Q;aak-2 ne-
matodes (Fig. 2) and double mutants 128Q;aak-2;daf-16 do not
show an additive effect. This could suggest that aak-2 and daf-
16may operate in the same pathway to promote the touch recep-
tor neuron function. However, touch responses in single and
double mutants is very low, ∼10–12%, and we cannot rule out
the possibility that touch response can no longer be decreased
and a synergistic effect could be missed in 128Q;aak-2;daf-16 ani-
mals. To gainmore insight into this question, we performed cell-
speciﬁc rescue of aak-2 and daf-16, into the single and double
mutants. To this end, we produced transgenic nematodes carry-
ing extrachromosomal arrays expressing a cDNA for aak-2 or daf-
16 in touch receptor neurons. On the one hand, we introduced
Figure 1. aak-2/AMPKα is neuroprotective in 128Q worms. (A) Ablation of the aak-2 gene results in enhancement of the touch phenotype in 128Q worms. (B) Metformin
alleviates the touch phenotype of 128Q animals, without affecting the behaviour of 19Qworms. (C) Metformin rescue of theworms dependsmostly on the presence of the
aak-2 gene. In all panels, values are mean ± SEM (N = 3 with a total of at least 100 animals tested per condition). ANOVA tests, with Tukey post hoc analysis. Ns: not
signiﬁcant. ***P < 0.001.
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arrays expressing aak-2 into the 128Q, 128Q;aak-2 and 128Q;aak-2;
daf-16 animals. On the other hand, we introduced arrays expres-
sing daf-16 into 128Q, 128Q; daf-16 and 128Q;aak-2;daf-16 animals.
We generated and analysed two independent strains per array
(Fig. 2). Overexpression of aak-2 or daf-16 rescued neuronal dys-
function of 128Q animals in a cell-autonomous manner (Fig. 2).
However, the level of rescue differs substantially between geno-
types. The daf-16 expression rescues the touch phenotype of all
three strains into which it was introduced (128Q, 128Q;daf-16
and 128Q;aak-2;daf-16) to levels comparable with 19Q nematodes
(Fig. 2). This suggests that daf-16 expression in touch receptor
neurons is sufﬁcient to restore a normal activity of these cells.
This also suggests that daf-16 acts downstream of aak-2 since
daf-16 does not need aak-2 to alleviate the touch response pheno-
type induced by polyQ-expandedHtt expression. In contrast, aak-
2 expression alleviates the touch response of 128Q;aak-2 animals
to the same level of 128Q, but has no effect in either 128Q or 128Q;
aak-2;daf-16 animals (Fig. 2). Why expression of aak-2 cannot
raise the mechanosensory response of 128Q animals to levels
comparable with 19Q animals, as daf-16 does? This can be attrib-
uted to AMPK operating as an obligate heterotrimer (AMPKα,
AMPKβ and AMPK γ) in a range of species, from yeast to humans.
Therefore, re-introducing aak-2/AMPKα alone cannot raise AMPK
function above endogenous levels, since aak-2 would need the
other two components of the enzyme (AMPKβ and AMPKγ) in
equimolar amounts, to be able to phosphorylate its substrates,
including DAF-16. Nonetheless, failing of aak-2 to rescue the
touch phenotype of 128Q;aak-2;daf-16 animals means that
daf-16 is epistatic over aak-2 and so daf-16may act directly down-
stream of aak-2 to protect neurons from 128Q cytotoxicity.
We previously showed that increasing the activity of sirtuin
sir-2.1/SIRT1 protects 128Q nematodes from neuronal dysfunc-
tion in a daf-16-dependent manner (36,37). Subsequent studies
showed that SIRT1 has neuroprotective effects in mouse models
of HD (39,40). Given that SIRT1 may activate AMPK to ameliorate
age-related diseases (41), we tested whether sir-2.1/SIRT1 protec-
tion may be dependent AMPK in 128Q nematodes. To this end,
we introduced a null allele of aak-2 in a strain of 128Q animals
that has increased sir-2.1/SIRT1 dosage and that is devoid of
background mutations with life extension effects (42). The pro-
tection from neuronal function elicited by increased sir-2.1/
SIRT1 dosage in 128Q animals was completely abolished by
aak-2 LOF (Supplementary Material, Fig. S2), suggesting that
sirtuin protection may be dependent on AMPK activity in HD
neurons. Thus, SIRT1 may engage FOXO (36,37) and AMPK (this
study)-dependent mechanisms to compensate for the neuronal
cytotoxicity of mHTT species.
AMPKα is protective in mouse striatal cells derived
from knock-in HD mice
To test whether the neuroprotective role of AMPKα observed in
128Q nematodes is conserved in a mammalian model of HD,
we manipulated the activity of AMPKα in striatal cells derived
from the HdhQ111 knock-in mouse model of HD (30). Striatal
cells expressing mHtt (109Q/109Q) are abnormally susceptible
to cell death as induced by serum deprivation (30), a phenotype
that is suitable for identifying modiﬁers of cell vulnerability
in HD (30,43). The analysis of the expression levels of the two
AMPK catalytic isoforms present in mammals, AMPKα1 and
AMPKα2, by quantitative real-time polymerase chain reaction
(qRT-PCR) shows that both types of mRNAs are present in striatal
cells derived from the HdhQ111 mice (Fig. 3A). This analysis
primarily suggested that AMPKα1 mRNA levels are higher in
109Q/109Q cells than those in 7Q/7Q cells whereas AMPKα2
mRNA levels were lower in 109Q/109Q cells than those in 7Q/7Q
Figure 2. aak-2 requires daf-16 for neuroprotection in a tissue-speciﬁc-dependentmanner. The deletion of both daf-16 and aak-2 induce a similar enhancement of the touch
phenotype. Combining both mutations do not show a synergistic effect, neither an additive effect, suggesting that both genes induce neuroprotecttion though the same
pathway. Rescuing aak-2 and daf-16 in mechanosensory neurons rescues the touch phenotype at different levels. Rescue of the touch phenotype by aak-2 overexpression
requires daf-16, further suggesting that both work in the same signalling pathway. Values aremean ± SEM (N = 3 with a total of at least 100 animals tested per condition).
ANOVA tests, with Tukey post hoc analysis were used. ns: not signiﬁcant. **P < 0.01 and ***P < 0.001.
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cells (Fig. 3A). Confocal analysis shows that AMPKα1 is localized
in the cytoplasm and nucleus of 7Q/7Q and 109Q/109Q cells
(Fig. 3B) and that there is more AMPKα1 expression in 109Q/
109Q versus 7Q/7Q cells with AMPKα1 proteins being primarily
detected in the nucleus (Fig. 3C and D), which corroborates the
trend detected at the mRNA level. Consistently with previous
studies (44), AMPKα2 is mostly nuclear in mouse striatal cells
(Fig. 3B). Confocal analysis also shows that there is more
AMPKα2 in 109Q/109Q cells compared with 7Q/7Q cells (Fig. 3C).
This contrasts with the trend observed at the mRNA level,
suggesting that AMPKα2 proteins are prone to stabilization in
109Q/109Q and 7Q/7Q cells.
It has been suggested that overactivation and nuclear trans-
location of AMPKα1 may exacerbate cell death during the late
phases of the pathogenic process in HD as inferred from the
study of HD post-mortem brains and mouse models of HD,
such as symptomatic R6/2mice (12weeks) probably due to oxida-
tive stress (27,28). It has also been suggested that AMPK
phosphorylation and activation is associated to cytotoxicity in
striatal cell lines derived from HdhQ111 knock-in mouse (27,28).
However, when we add the AMPK activator metformin (2 m) to
these cells (109Q/109Q cells), we observed an increase of AMPKα-
phosphorylated levels in the nucleus and cytoplasm of 7Q/7Q
and 109Q/109Q cells, with a trend towards a slightly stronger
effect in the cytoplasm of 109Q/109Q cells (Fig. 4A and B). We
also observed thatmetformin treatment reduced the susceptibil-
ity to cell death induced by serum deprivation in mHtt striatal
cells (Fig. 5A), a phenotype previously shown to be dependent
on mHtt expression (37), with no effect detected in normal Htt
striatal cells (Fig. 5A), which is accompanied by increased phos-
phorylation of AMPKα (Fig. 5A). Moreover, while RNAi silencing
of AMPKα2 does not change the mortality rate of serum-
deprivated 109Q/109Q cells (data not shown), siRNA against the
more abundant form AMPKα1 strongly increased the mortality
of 109Q/109Q cells with no effect detected in 7Q/7Q cells. This
suggests that AMPKα1 has a protective role in cells expressing
Figure 3. Nucleo-cytoplasmic expression of AMPKα1 and AMPKα2 in 7Q/7Q and 109Q/109Qmouse striatal cells. (A) RT-PCR analysis of the expression of AMPKα subunits
shows that AMPKα1 mRNA levels are higher in 109Q/109Q cells versus 7Q/7Q cells and that AMPKα2 mRNA levels are lower in 109Q/109Q cells versus 7Q/7Q cells. Values
are mean ± SD (N = 3 in triplicate). ***P < 0.001. (B) Representative images of antibody staining of both subunits showing that AMPKα1 and AMPKα2 have variable nucleo-
cytoplasmic distributions across 7Q/7Q and 109Q/109Q cells. Scale bar is 20 μ. (C) Quantiﬁcation of nuclear signal intensities for AMPKα1 andAMPKα2 showing that there
is more AMPKα1 in 109Q/109Q cells compared with 7Q/7Q cells, which is also observed for AMPKα2. Values are mean ± SEM (N = 3 for a total of at least 90 cells tested per
condition). ***P < 0.001. (D) Quantiﬁcation of nucleo-cytoplasmic distribution for AMPKα1 showing that there ismore AMPKα1 in the nucleus of 7Q/7Q cells, which is more
pronounced in 109Q/109Q cells. Values are mean ± SEM (N = 3 for a total of at least 90 cells). ***P < 0.001. Statistics were performed using t tests in all panels.
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Figure 4. Nucleo-cytoplasmic expression of AMPKα-phosphorylated in 7Q/7Q and 109Q/109Q mouse striatal cells. (A) Representative confocal images illustrating that
AMPKα-phosphorylated is evenly distributed in the nucleus and cytoplasm in 7Q/7Q and 109Q/109Q cells. Scale bar is 20 μm. (B) The upper two panels show an
example of the AMPKα-phosphorylated signal along a line (yellow) that crosses the cytoplasm and nucleus. The blue curve shows DAPI staining, pointing out the
region covered by the nuclei, and the green line shows ﬂuorescent due to AMPKα-phosphorylated staining. Colour boxes indicate the area used for the quantiﬁcation
of AMPKα-phosphorylated signals on either side of the nuclear membrane. The lower panel shows the levels of AMPKα-phosphorylated signals, with increase of the
signal in both the cytoplasmic and nuclear compartment induced by metformin treatment of 7Q/7Q and 109Q/109Q cells. Values are mean ± SD (N = 3 for a total of at
least 50 cells/condition). ANOVA tests, with Tukey post hoc analysis for each genotype, were used. *P < 0.05, **P < 0.01 and ***P < 0.001.
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mHtt (Fig. 5B). Next, we tested for the effect of AMPK activation in
these cells. To this end, we introduced in these cells a gain of
function form of AMPKγ1, the regulatory subunit of the enzyme
that induces a constitutively active state in the catalytic subunit
AMPKα. We elected to manipulate AMPKγ1 levels as a way to test
for the effects of different types of AMPK subunits on AMPK acti-
vation and cell survival. Overexpression of AMPKγ1 gain of func-
tion (AMPKγ1GOF) induces phosphorylation of AMPKα paralleled
with an increase of the survival ofmouse striatal cells expressing
mHtt with no effect detected in mouse striatal cells expressing
normal Htt (Fig. 5C). These effects occur without perturbing the
expression of mHtt (Fig. 5C). For all experiments based on using
striatal cells from HDmice, it is noticeable that we used low pas-
sage (P9–P11) mouse striatal cells, which is an important consid-
eration since themouse striatal cell lines expressingmHtt tend to
lose their cell vulnerability phenotype at higher passages. Our re-
sults thus suggest that changes in the brains fromHD patients, at
the time of death, and in R6/2mice, at an advanced stage of path-
ology (12 weeks), in terms of AMPKα activity and outcome on cell
survival may greatly differ from changes observed inmodels that
recapitulate an earlier or milder phase of cytotoxicity in HD such
as mouse striatal cells derived from HdhQ111 knock-in mice.
Collectively, these data suggest that raising AMPK activity
protects striatal cells from the vulnerability to stress that may
be induced by mHtt expression in HD.
Raising AMPK activity reduces the amount of soluble
mHTT inmouse striatal cells derived fromHdhQ111mice
AMPK can promote protein clearance in response to cellular
stress induced by nutrient deprivation, through inhibition of
mTOR (45). Additionally, AMPK can activate autophagy and pro-
tein clearance inmuscle cells through activation of the longevity-
promoting factor FOXO3a (46). AMPK can alsomodulate the func-
tion of the proteasome under speciﬁc metabolic conditions such
as nutrient deprivation (3). Therefore, we tested whether allevi-
ation of stress vulnerability of 109Q/109Q striatal cells by AMPK
activation (Fig. 5A–C) might be associated to a reduction of
mHTT load. To this end, we assayed 109Q/109Q striatal cells in
whichwehadover-expressedAMPKγ1GOFusing anultrasensitive
Figure 5.AMPKhas a protective function in and in vitromodel of HD. (A) Growing striatal cells inmetformin 2 m reducesmortality induced by serumdeprivation in 109Q/
109Q mouse striatal cells (***P < 0.001, N = 3). The right panel shows representative western blots to show that AMPKγ1GOF induces phosphorylation of AMPKα in striatal
cells. The levels of Htt do not change. (B) Silencing AMPKα1 by RNAi in 109Q/109Q mouse striatal cells enhances cell mortality in response to serum deprivation with no
effect detected in 7Q/7Q cells (***P < 0.001; ns: not signiﬁcant; N = 3). The right panel shows representative western blots in which AMPKα1 siRNAs reduce AMPKα1 protein
levels (N = 3,mean ± SD = 0.4 ± 0.1, P = 0.018)with no change detected in the level ofHtt (N = 3,mean ± SD = 1.1 ± 0.5, P = 0.71). (C) Overexpression of an over-activated formof
AMPKγ1, AMPKγ1GOF, reduces mortality of 109Q/109Q cells in response to serum deprivation (**P < 0.005, N = 3). The right panel shows representative western blots in
which AMPKγ1GOF expression increases AMPKγ1 protein levels (as detected using a c-Myc tag), phosphorylated AMPKα1 levels (N = 3, mean ± SD = 1.6 ± 0.1, P = 0.027).
The effect on Htt levels is addressed in (D). (D) Overexpression of the over-activated form of AMPKγ1 induces clearance of misfolded mHtt (***P < 0.001, N = 3). The right
panel shows representative western blots in which AMPKγ1GOF increases AMPKγ1 levels (as detected using a c-Myc tag), and phosphorylated AMPKα levels (N = 4,
mean ± SD = 1.7 ± 0.4, P = 0.021). In all panels: ns: not signiﬁcant.
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method that relies on antibody staining and Förster resonance
energy transfer for the speciﬁc quantiﬁcation of solublemHTT le-
vels (47). Interestingly, 109Q/109Q cells transfected with AMPKγ1-
GOF show a drastic reduction of soluble mHtt levels (Fig. 5D),
suggesting that raising AMPK activity protects mouse striatal
cells from cell vulnerability by reducing soluble mHtt levels.
Expression of AMPKγ1GOF protects the mouse striatum
from mutant Htt protein load
Our results from the C. elegans and mouse striatal cell models of
HD pathogenesis consistently suggest that AMPK has neuropro-
tective effects against the early phases (neuronal dysfunction)
or features (cell vulnerability) of mHtt cytotoxicity. Next, we
tested whether AMPK protection may also occur in vivo in the
mouse brain. To this end, we used a model in which expression
of N-terminal Htt in the striatum using lentiviral vectors produce
neurodegeneration at 6–7weeks. Thismurinemodelmay be con-
sidered a mild model of proteotoxic stress in HD since these ani-
mals are born free of mHtt and since lentiviral vectors elicit a
moderate level of mHtt expression. We co-injected C57Bl/6J
mice bilaterally (i.e. in each of the striatum hemispheres) with
lentiviral vectors expressing Htt171-82Q plus saline (left hemi-
sphere: control) andHtt171-82Q +AMPKγ1GOF (right hemisphere:
test) (Fig. 6A). Seven weeks after injection, animals were sacri-
ﬁced and DARPP32 (Dopamine- and cAMP-regulated phospho-
protein, a neuronal marker well expressed by the medium
spiny neurons of the striatum which are particularly vulnerable
in HD) and ubiquitin (UBI) staining were used to monitor the
level of striatal pathology (Fig. 6A). The lesion size of the animals
over-expressing AMPKγ1GOF is signiﬁcantly reduced by 27%
compared with controls (Fig. 6B), suggesting that AMPK activa-
tion can slow-down the neurodegenerative process induced by
mHTT expression in the brain. In contrast, the total number of
UBI positive aggregates shows no signiﬁcant change (Fig. 6B),
suggesting that AMPK activation protects through mechanisms
that do not involve removal of inclusion bodies of mHTT.
Discussion
Premanifest or early-stage symptoms of HD are increasingly ac-
cessible to the follow-up studies and, potentially, diseasemodiﬁ-
cation in human patients (48). At these stages of HD, cellular
dysfunction and vulnerability may represent an important and
targetable component of the disease compared with later stages
of HD in which striatal cell loss is a prominent feature of the dis-
ease. It, thus, becomes essential to investigate the activity of HD
targets in model systems that recapitulate the early and revers-
ible components of the disease process such as neuron dysfunc-
tion before cell death and neuronal tissue vulnerability. We
previously showed that activation of cell survival and longevity
pathways such as the sir-2.1 and daf-16 pathway protects from
such components of the pathogenic process in HD (29,36,37).
Among these pathways, AMPK stands as a sensor of energy
state and guardian of energy homeostasis that may protect
the brain from insults such as stroke and neurodegenerative
disease-associated proteins.
Like many other HD targets at the cross-roads of signalling
pathways that are essential for cellularmaintenance and cell sur-
vival, AMPK is part of a large network of highly interconnected
genes that may change behaviour depending on the strength of
the proteotoxic stress and stage of the pathogenic process in
HD. In this context, it is important to understand what may be
the consequence of activating or inhibiting such targets across
several phases of the pathogenic process in HD. Additionally,
the net outcome of manipulating a highly connected (hub gene)
target is likely to reﬂect the balance between a series of protective
effects on the one hand and a series of aggravating effects on the
other hand, with each type of effects potentially engaging differ-
ent neighbours and downstream targets. This balance is highly
sensitive to the genetic and biological status of any one model
in which the target is manipulated. Here, we used highly con-
trolled models of HD pathogenesis (staged nematode strains,
low-passage mouse striatal cells, calibrated delivery of Htt to
mouse striata) to investigate the effects of manipulating AMPK
activity on a cardinal component that may underlie the dynamic
of HD, namely constitutive cell vulnerability, a cellular state that
may promote the early dysfunction and demise of HD neurons
and that may be associated to ‘build-in deﬁciency’ of stress re-
sponse mechanisms such as those under the control of FOXO3a
(29). Our genetic data suggest that AMPK primarily protects from
such constitutive and early-stage features of the pathogenic
process in HD, with capacity to reduce the ultimate level of
neurodegeneration that is progressively induced by misfolded
Htt expression. Noticeably, AMPKα1 levels are increased in
mouse striatal cells expressing mHtt and AMPKα1 silencing ag-
gravates the vulnerability of these cells to cell death induced by
serum deprivation, suggesting that AMPKα1 has a compensatory
and protective role in these cells.
Our ﬁndings contrastwith data from Ju et al.who reported that
the function of AMPK might be over-activated, paralleled by an
AMPKα1 translocation to the nucleus, in symptomatic mouse
models of HD and post-mortem HD brain tissues as a conse-
quence of oxidative stress (27,28). These latter studies usedmod-
els that recapitulate a fast developing, and rather advanced
phase, of HD pathology (symptomatic R6/2 mice at 12 weeks) in
mice or a late phase of the disease in human subjects (post-mor-
tem HD brain). Their results contrast with the observation that
giving metformin to a transgenic model of HD (R6/2) has been
shown to increase the brain ratio of AMPKα-phosphorylated ver-
sus non-phosphorylated, an effect accompanied by an amelior-
ation of some of the phenotypes associated with the disease
(26). Here, we used models that recapitulate the early (neuronal
dysfunction in young C. elegans adults), constitutive (cell vulner-
ability of mouse striatal cells) and progressive (neurodegenera-
tion ultimately induced by lentiviral delivery in the mouse
brain) phases of HD pathology to observe that AMPK activation
is protective whether elicited by genetic or pharmacological
means. We propose that AMPK activity may have diametrically
opposing roles in HD depending on the biological phase of
the pathogenic process in HD. Collectively, our data suggest a
model in which the function of AMPK has a protective role in
the early to intermediate phases of the pathogenic process in
the disease, by inducing pro-survival pathways that prevent the
cytotoxicity induced by soluble mHTT. Here, it is interesting to
note that AMPK activators such as A769662 may be protective
in mouse cell models of HD (C. Walter and H.P. Nguyen, personal
communication) as we observedwith the genetic and pharmaco-
logical activation of AMPK in our study. Collectively, the results in
the two studies strongly emphasize AMPK and its activation as a
valuable approach to preserve the capacity of striatal neurons to
ﬁght the consequences of mHTT toxicity and maintain homeo-
stasis over the early, manageable phases of the pathogenic pro-
cess in HD. As the organism ages or as cells are less capable of
coping with proteotoxic stress and its consequences, AMPK
might becomemore active by an overwhelming quantity of stress
signals, and its activity may become lethal to the cell. Thus, care-
ful attention should be given on how to test for the effects of
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AMPK modulation in pre-clinical studies aiming at the develop-
ment of disease-modifying strategies.
Our data corroborate the important notion that longevity-pro-
moting pathways such as the AMPK pathway may help neurons
to deal with the proteotoxic stress that is chronically induced in
neurodegenerative disease bymisfolded protein expression such
as mHtt (29,36,37,49), therefore sustaining the capacity for bio-
logical resilience to proteotoxic stress in HD cells and tissues.
This is particularly important as biological resilience to
proteotoxic stress may be impaired at an early stage of the HD
process through the repression of the longevity-promoting and
neuroprotective factor FOXO3 by increased Ryk signalling to the
nucleus (29). Since AMPKmay directly regulate FOXO3 protective
activity (38), AMPK activators could provide a way to restore an
efﬁcient response of FOXO3 to proteotoxic stress in HD neurons.
Additionally, our data in mouse striatal cells and in the mouse
brain suggest that AMPK may induce mechanisms that clear
the cell from toxic soluble species, without affecting the presence
Figure 6. In vivo activation of AMPK rescues striatal cell degeneration in amousemodel of HD. (A) Diagram showing the treatment of both sides of the brains of micewith
lentiviruses expressing the N-terminal fragment of mHtt [Htt171-82Q (Htt in the diagram)], or the AMPKγ1GOF. Below is shown a representative picture of DARPP32
staining of the sections of the brains of these mice, which highlights the area of the lesion caused by mutant Htt. The right panel shows the analysis of the volume of
the lesion caused by mutant Htt, with overexpression of AMPKγ1GOF reducing cell death. Values are mean ± SEM. *P < 0.05 (P = 0.03, N = 13). (B) Representative pictures
showing UBI staining and pointing out to inclusion bodies. The right panel shows the quantiﬁcation of the number of UBI-positive aggregates. Values are mean ± SEM.
The overexpression of AMPKγ1GOFdoes not change the number of inclusion bodies (P = 0.87,N = 13). Statistics use theWilcoxon test for paired samples. ns: not signiﬁcant.
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of inclusion bodies. Examples of such apparent discrepancy are
not rare in the literature, since it was shown early on that treat-
ment with the caspase inhibitor Z-VAD-FMK increased the sur-
vival of mouse striatal cells transfected with mHtt, but failed to
diminish nuclear and cytoplasmic inclusions. In the same way,
another substance tested in HD models, Z-DEVD-FMK, signiﬁ-
cantly reduced inclusion bodies without increasing the survival
of cells (50). Saudou et al. (51) showed that exposure to conditions
that suppress the formation of inclusion bodies resulted in an in-
crease in mHtt-induced cell death. Also, Zala et al. (52) reported
that in rat primary striatal cultures infected with the same
lentivirus encoding Htt171-82Q used in our study, the ciliary
neurotrophic factor and brain-derived neurotrophic factor
prevented neuronal degeneration while increasing the number
of ubiquitinated nuclear inclusions. Finally, twomore teams, Ar-
rasate et al. and Mitra et al. (53,54) showed data strongly
suggesting that inclusion bodies may be the consequence of a
protective cellular mechanism.
Interestingly, our data suggest that AMPK activators such as
metformin may protect from the early phases of the pathogenic
process inHD. It has been shown thatmetforminmayhave antic-
ancer (55) and antidiabetic (56) activities through AMPK-inde-
pendent pathways. However, our experiments indicate that the
rescue of neuronal impairment of the polyQ-expressing animals
mediated by metformin is mostly dependent on the presence of
aak-2/AMPKα. This strongly suggests that the AMPK function is
required for a beneﬁcial effect. Metformin has been shown to
be able to extend health- and life-span in C. elegans (57) and in ro-
dents (58) by mimicking caloric restriction. It has been proposed
recently that lifespan extension in worms, treated with metfor-
min, ismediated by inhibition of themicrobial folate andmethio-
nine metabolism by this drug (59), an effect which is AMPK-
dependent. Hence, itmay be possible thatmetforminmay be res-
cuing, at least partially, neuronal impairment of 128Q worms
through mimicking caloric restriction. Another mechanism by
whichmetforminmay protect frommHTT cytotoxocity is the re-
duction of solublemHTT levels, as revealed by our data inmouse
striatal cells. As recently suggested in other studies of stress
response drugs such as rapamycin (60) and latrepirdine (61), it
is interesting to speculate that, besides a chronic exposure to
AMPK activators that could have unwanted effects in the context
of HD, intermittent, low-dose or pre-conditioning treatmentwith
AMPK activators might constitute a safer though efﬁcient way to
activate AMPK activity and slow-down disease progression in
early-stage HD. The purpose of our study was to generate a
proof-of-concept that AMPK activation protects against the cyto-
toxic effects of mHTT in vivo, in the mouse brain. Future studies
will test whether AMPK activators such as metformin and other
compounds of potential interest for AMPK activation in neurons
with proteotoxic stress (61–64), in the form of chronic, intermit-
tent or pre-conditioning treatments, may have neuroprotective
effects as the pathogenic process develops in transgenic and
knock-in mouse models of HD. Here, it is important to note
that since there is more AMPKα1 in 109Q/109Q mouse striatal
cells, and since AMPKα1 silencing aggravates cell death in
these cells whereas raising AMPK activity has opposite effect,
AMPKα1 increase may represent a compensatory and protective
response against mHtt expression and the early phases of the
HD process.
In sum, our data suggest that AMPK activation represents a
compensatory response and useful approach for protecting
neurons that, in the caudate nucleus, are targeted by the early
phases of the proteotoxic and cellular stress induced by mHTT
expression in HD.
Materials and Methods
Nematode strains and culture
Nematodes were grown as described elsewhere (65). All strains
were maintained and assayed at 20°C. Transgenic C. elegans
nematodes stably expressing humanHtt fused to GFPwere previ-
ously described (29,34,37,66). Non-dyf sir-2.1 over-expressingmu-
tants were obtained from the laboratory of David Gems (42). The
originating parent strain, LG100, has been described as having a
Dyf (dye defective mutant) phenotype responsible, at least in
part, regarding the pro-lifespan effects. Table 1 provides a de-
tailed list of strains used in this study. All strains were out-
crossed to wild-type background (Bristol N2) at least four times.
Genetic manipulation in C. elegans
To produce the constructs for the tissue-speciﬁc rescue experi-
ments, we ampliﬁed the promoter of the mec-3 gene using the
following primers: forward RVM13 5′-GGGGACAAG TTTGTACA
AAAAAGCAGGCTCCTGCAGGTACCCGGAGTAGTTG-3′ and reverse
RVM14 5′-GGGGACAACTTTTGTATACAAAGTTGTAATGCGCGAAA
TTGTGGCTAC TC-3′. We cloned this PCR product in pDONR-P1-
P5r using the system Gateway (Invitrogen). We then ampliﬁed
the cDNA of aak-2, using the following primers: forward RVM18
5′-GGGGACAACTTTGTATAC AAAAGTTGGAAAAATGTTTTCTCAT
CAAGATCGAGA C-3′ and reverse RVM19 GGGGACCACTTTGTAC
AAGAAAGCTGGGTATTAACGAGC CAGTGTTCCAATCAATG-3′. We
ampliﬁed the cDNA of daf-16 fused to GFP from a plasmid from
the Driscoll Lab (Rutgers University, USA) using the following pri-
mers: primer RV177 5′-GGGGACAACTTTGTATACAAAAGTTGAAA
ATGATGGAGATGCTGGTAG ATC-3′ and reverse RV178 5′-GGGGA
CCACTTTGTACAAGAAAGCTGGGTATTATAG TTCATCCATGCCAT
GTGTA-3′. Both PCR products, aak-2 and daf-16::GFP, were cloned
into pDONR-P5-P2 using Gateway. The mec-3 promoter and each
cDNAwere assembled separately, using Gateway, within a destin-
ation vector that contains the transcription terminator from the
unc-54 gene, pHP2 (69).
For overexpression experiments, 20 ng/μl of the DNA contain-
ing the cDNA of interest was injected into worms, together with
pPD118.33 (a plasmid encoding a pharyngeal-expressed GFP as a
marker). pPD118.33 is a gift from A. Fire. DNA was injected at a
total ﬁnal DNA concentration of 120 ng/μl, using previously de-
scribedmethods (70). Several independent stable strains contain-
ing the transgenes were isolated, and at least two strains of each
construct were analysed.
Behavioural assays in C. elegans
Touch test on posterior lateral microtubule neurons were per-
formed by scoring for 10 touches on the tail of the animal for
∼100 animals per genotype, as described elsewhere (66). We plot-
ted mean values for responsiveness and analysis of variance
(ANOVA) test, with Tukey’s multiple comparison test, were used
for statistical analysis.
Pharmacological assays in C. elegans
Synchronized L1 larvae were grown in the liquid culture as de-
scribed previously (36) in the presence ofmetformin 2 m (1,1-di-
methylbiguanide hydrochloride, Sigma-Aldrich ref. D150959) or
vehicle (dimethylsulfoxid, DMSO) as a control. Once they reached
adulthood (48 h or so), animals were placed in empty NGM plates
and allowed to rest for an hour. Animalswere then assayed for re-
sponse to light touch as described above.
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Production of AMPKγ1GOF plasmid for use in cell
or mouse testing
Mouse cDNA coding for the gamma1 subunit of AMPK tagged
with c-Myc in a pDONR-221 vector was produced by PCR three
rounds of PCR ampliﬁcation using as a template a plasmid con-
taining the cDNA of AMPKγ1, with a GOF mutation (R69Q) (a gift
from Benoit Viollet, Institut Cochin, France). We used the follow-
ing forward primers to add the c-Myc tag and Kozak sequence to
AMPKγ1: RV69 5′-GGGGACAAGTTTGTACAA AAAAGCAGGCTGC
CGCCACCATG-3′, RV70 5′-AAAGCAGGCTGCCGCCACCAT GGAAC
AAAAACTTATTTCTGA AG-3′and RV71 5′-GAACAAAAACTTAT
TTCTGAA GAAGATCTGATGGAGTCGGTTGCTGCAGAG-3′. We
used as a reverse primer RV72 5′-GGGGACCACTTTGTACAA
GAAAGCTGGGTATCAGGGCTTCTTCTCTCCTC-3′. The resulting
product of the third round of PCR was cloned into pDONR221 by
recombination in vitro, using the Gateway® Cloning technology
following the protocol provided by the manufacturer (Life Tech-
nologies, Carlsbad, CA, USA). From the resulting entry vector,
containing c-Myc-AMPKγ1GOF, we transferred this cDNA to
both pcDNA3.1 (for cell transfection; see the Cell death assays
section) and the SIN-cPPT-PGK-WHV Gateway vector (for in vivo
manipulation of mouse brains; see the Injection of lentiviral
vectors to the mouse brain section).
Mouse striatal cell culture
Weused striatal cell lines expressing normal (7Q/7Q) or expanded
(109Q/109Q) Htt derived from the HdhQ111 knock-in mice (30).
These cells were handled as previously described (43) and,
importantly, used at low passages (P9–P11).
Cell death assays
Cell death tests were performed as described previously inducing
cell death by serum deprivation (71). Mouse striatal cells were
seaded in 24-well plates. Cells were genetically manupulated
using cDNAs (see the ‘production of AMPKγ1GOF’ section) or siR-
NAs (see below) or pharmacologically treated using metformin
(1,1-dimethylbiguanide hydrochloride, Sigma-Aldrich ref.
D150959) or vehicle (DMSO) for 24 h, prior to serum deprivation
for an additional 24 h. Cells were ﬁxed with PFA 4% and stained
with 4′,6-diamidino-2-phenylindole (DAPI). Cells were then
mounted on slides with polyvinyl alcohol. We examined dead
cells each of which showed picnotic nuclei. Paired t tests were
used for statistics.
Genetic perturbation in mouse striatal cells
cDNAs (2 μg)were transfected using JetPEI fromPolyPlusTransfec-
tion (Illkirch, France) following the protocol of the manufacturer.
The siRNAs were transfected using JetSI-ENDO from PolyPlus
Transfection (Illkirch, France) following the protocol of the
manufacturer. The siRNAs were obtained from Euroﬁns MWG
Operon (Ebersberg, Germany). The targeted sequences are as fol-
lows: AMPKα1_1, 5′-AACGAATTGAATGCTGTATAA; AMPKα1_2,
5′-AAATGGAAGGTTGGACGAAAA-3′; AMPKα2_1, 5′-AAAGTCA
GAAGTGATGAATAG-3′; AMPKα2_2, 5′-AAATGGAAGGTT GGAC
Table 1 Names and genotypes of the C. elegans strains used in this study.
Straina Genotype References
Bristol N2 Standard wild-type (65)
CF1038 daf-16(mu86)-I (67)
GA468b geIn3[sir-2.1; rol-6]-I (42)
RB754 aak-2(ok524)-X (13)
ID161c igIs161[mec-3p::htt57-19Q::GFP; lin-15(+)]-? (66)
ID5 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-? (66)
ID1400 igIs161[mec-3p::htt57-19Q::GFP; lin-15(+)]-?; aak-2(ok524)-X This work
ID1401 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X This work
ID1402 igIs161[mec-3p::htt57-19Q::GFP; lin-15(+)]-?; daf-16(mu86)-I This work
ID1403 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; daf-16(mu86)-I This work
ID1404 igIs161[mec-3p::htt57-19Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; daf-16(mu86)-I This work
ID1405 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; daf-16(mu86)-I This work
ID1406 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; geIn3[sir-2.1; rol-6] This work
ID1407 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; geIn3[sir-2.1; rol-6]; aak-2(ok524)-X This work
RVM100 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; vltEx1[mec-3p::aak-2; myo-2::GFP] This work
RVM101 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; vltEx2[mec-3p::aak-2; myo-2::GFP] This work
RVM102 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; vltEx3[mec-3p::daf-16; myo-2::GFP] This work
RVM103 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; vltEx4[mec-3p:: daf-16; myo-2::GFP] This work
RVM104 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; vltEx5[mec-3p::aak-2; myo-2::GFP] This work
RVM105 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; vltEx6[mec-3p::aak-2; myo-2::GFP] This work
RVM106 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; daf-16(mu86)-I; vltEx7[mec-3p::daf-16; myo-2::GFP] This work
RVM107 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; daf-16(mu86)-I; vltEx8[mec-3p:: daf-16; myo-2::GFP] This work
RVM108 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; daf-16(mu86)-I;vltEx9[mec-3p::aak-2; myo-2::GFP] This work
RVM109 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; daf-16(mu86)-I;vltEx10[mec-3p::aak-2; myo-2::GFP] This work
RVM110 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; daf-16(mu86)-I; vltEx11[mec-3p:: daf-16; myo-2::GFP] This work
RVM111 igIs5[mec-3p::htt57-128Q::GFP; lin-15(+)]-?; aak-2(ok524)-X; daf-16(mu86)-I; vltEx12[mec-3p:: daf-16; myo-2::GFP] This work
aAll mutant strains were out-crossed to wild-type background (Bristol N2) at least four times. N2, CF1038, GA468 and RB754 were provided by the Caenorhabditis Genetics
Centre (University of Minnesota, MN, USA).
bThe GA468 strain contains a sir-2.1 overexpressing transgene from the strain LG100 (68), but it does not contain the dyf(?) mutation present in LG100 (42).
chtt57 refers to aminoacids 1–57 of human Htt.
Human Molecular Genetics, 2016, Vol. 25, No. 6 | 1053
GAAAA-3′. For pooled siRNA experiments, each siRNA was used
at a concentration of 33 n. Individual siRNAs were tested at
100 n.
Real-time polymerase chain reaction
The relative expression of Htt, Prkaa1 (mouse gene encoding
AMPKα1) and Prkaa2 (mouse gene encoding AMPKα2) was mea-
sured by RT-PCR using a thermal-cycler fromApplied Biosystems
(ViiATM 7 Real-Time PCR System; Life Technologies Corporation,
Carlsbad, CA, USA) using the following TaqMan® gene expression
assays: mm01213820_m1 for Htt, Mm012164789_m1 for Prkaa1,
and Mm01296700_m1 for Prkaa2. We used for ampliﬁcation the
TaqMan® 2× PCRMaster Mix fromApplied Biosystems (Life Tech-
nologies Corporation). β2-microglobulin (β2m) gene (assay kit
Mm00437762_m1) was used as a housekeeping gene. The RT-
PCR program was as follows: 1 cycle of 2 min at 50°C, followed
by 1 cycle of denaturation of 10 min at 95°C, continued by 40 cy-
cles of 15 s of denaturation at 95°C and 60 s of annealing and
polymerization at 60°C.
To detect polyQ expression inwormswe used Taqman probes
and primers from Integrated DNA Technologies (Coralville, IA,
USA). The sequence of probe and primers to detect the house-
keeping gene (pmp-3) are as follows: probe 5′-/56-FAM/TCC AGC
AAG/ZEN/TTC TCC AAA ATC TCC AGT G/3IABkFQ/-3′, forward
primer: 5′-AGG ACG ATCAGT TTCAAG GC-3′ and reverse primer:
5′-GTACCTCATCTACAGCTTCTC G-3′. For detection of the GFP
gene we used: 5′-/56-FAM/ATAACCTTC/ZEN/GGGCATGGCACT
CT/3IABkFQ/-3′, forward primer: 5′-CCTTCAAACTTGACTTCAG
CAC-3′ and reverse primer: 5′-TGGTGTTCAATGCTTCTCGAG-3′.
We used the same conditions and equipment described above.
Western blot analysis
Proteins from striatal cells were separated by sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis (SDS–PAGE) and ana-
lysed by western blot using the following primary antibodies:
mouse anti-htt (1HU-4C8, Millipore, 1:500), rabbit anti-AMPKα
(23A3, Cell Signaling, 1:1000), and mouse anti-actin (MP, 1:10000).
Secondary antibodies used: goat-anti-mouse IgG HRP-conjugated
(Bio-Rad), goat-anti-rabbit IgG HRP-conjugated (Bio-Rad). Proteins
were detected using ECL2 (ECL for actin) reagent (Pierce) and eval-
uated by densitometry and quantiﬁcation was performed using
ImageJ. For detection of AMPKα-phosphorylated, we used the rab-
bit anti-phospho-AMPKα (Thr172) (Cell Signaling, 1:1000). For de-
tection of AMPKα1, we used the mouse anti-AMPKα1 antibody
2B7 (1:1000, Abcam). For detection of AMPKα2, we used the rabbit
anti-AMPKα2 antibody ab3760 (1:500, Abcam). For detection of
AMPKγ1 labelled with the c-Myc tag, we used the rabbit anti-Myc
antibody 71D10 (1:1000, Cell Signaling).
Quantiﬁcation of soluble mHtt levels in mouse
striatal cells
Mutant Htt protein detection was performed as described previ-
ously (72). In brief, 5 μl lysate and 1 μl of antibody 2B7-Tb/MW1-
D2 (73) per well were transferred to a low volume 384-well plate
(Greiner). After incubation for 1 h under shaking wells, samples
were analysed with an EnVision Reader (Perkin Elmer) following
excitation at 320 nm (time delay 100 μs, window 400 μs, 100
ﬂashes/well). Time-resolvedﬂuorescence energy transfer signals
were collected as the background subtracted ratio between ﬂuor-
escence emission at 665 and 615 nm normalized to total protein
content.
Confocal analysis in mouse striatal cells
Expression of AMPK subunits or phosphorylated AMPKα was
analysed in 7Q/7Q and 109Q/109Q mouse striatal cells with or
without metformin treatment (see the Cell death assays section)
by using above-mentioned antibodies (see the Western blot ana-
lysis section). Mouse striatal cells were grown in a Nunc™ Lab-
Tek™ 8-chamber Slide System (8000 cells/well). After 48 h, cells
were ﬁxed and permeabilized using Cytoﬁx/Cytoperm™ kit (Bec-
ton, Dickinson and Company, Franklin Lakes, NJ, USA) following
the manufacturer’s protocol. Cells were then blocked with Dul-
becco’s phosphate buffered saline (DPBS) +0.1% Triton 100-X + 1%
bovine serum albumin (BSA) for 1 h at room temperature and in-
cubated overnight at 4°C with appropriate antibody (see above),
at a dilution of 1:100 in DPBS 0.1% Triton 100-X and 1% BSA.
The following day, cells were washed three times with DPBS for
10 min and incubated for 1 h and a half at room temperature
with secondary antibodies goat-anti-mouse Alexa Fluor 488 (In-
vitrogen, 1:200) and goat-anti-rabbit Alexa Fluor 555 (Invitrogen,
1:200) for detection of AMPKα subunits or goat-anti-rabbit Alex
Fluor 488 (Invitrogen, 1:200) for detection of phosphorylated
AMPKα. Cells were then washed with DPBS and subjected to
DAPI staining. After three more washes with DPBS, cells were
mounted in Mowiol plus ProLong® Antifade Reagent (Life Tech-
nologies, Thermo Fisher Scientiﬁc). Fluorescent signals were
quantiﬁed using an SP5 Leica Confocal Microscope (Leica Micro-
systems,Wetzlar, Germany).We kept the same settings in photo-
multipliers for each condition tested in order to ensure data
comparability. Imageswere analysed using ImageJ. The compari-
son of 7Q/7Q and 109/109Q cells was based on cell nuclei that
have a size of 150–250 pixels in each of the cell lines. To assess
cytoplasmic expression of AMPKα isoforms, nuclear AMPK sig-
nals as deﬁned byDAPI stainingwere blackened, and the remain-
ing signals were quantiﬁed. To assess the nucleo-cytoplasmic
distribution of AMPKα-phosphorylated, signals were quantiﬁed
on either side of the nuclear membrane along a diameter line
that crosses the cytoplasm and nucleus of each cell analysed.
Statistical analysis was performed using t tests or ANOVA tests
depending on the number of conditions compared in each
genotype.
In vitro validation of c-Myc-AMPKγ1GOF plasmid
expression
Of note, 293 T cells in six-well plates (750 000 cells/well) were
transfectedwith 5 μg of plasmid and cultured for 72 h. Cellular ly-
sates were harvested in a lysis buffer (20 m Tris, pH 7.5, 2 m
ethylene glycol tetraacetic acid, 150 m NaCl, 1% Nonidet P-40)
containing protease inhibitors and phenylmethanesulfonyl
ﬂuoride (SIGMA, Saint Louis, USA). Protein concentrations were
determined by the Bio-Rad protein assay kit (Bio-Rad, Munich,
Germany). Equal amount of proteins were loaded on 10% SDS–
PAGE and transferred to a nitrocellulose membrane (Schleicher
and Scuell Bioscience GmbH, Dassel/Relliehausen, Germany).
Immunoblottingwas performed using amousemonoclonal anti-
body (Ab-1, 1:200, Oncogene). Visualization of the protein was
achieved using ECL (Amersham Biosciences Europe GmbH, Frei-
burg, Germany) in a Fusion FX system. The functionality of the
vector was conﬁrmed in 293 T cells transfected with SIN-cPPT-
PGK-cMyc-AMPK-WHV where a strong signal corresponding to
the expected molecular weight of cMyc-AMPKγ1 was detected.
Lentiviral vectors encoding the ﬁrst 171 amino acids of mu-
tated (82 CAG) Htt (Htt171-82Q), and a lentiviral vector encoding
AMPKγ1, were produced as previously described (74,75). The
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particle content of viral batches was determined with a p24 anti-
gen enzyme-linked immunosorbent assay.
Injection of lentiviral vectors in the mouse brain
Thirteen adult 20 g male C57/BL6 mice were used (Iffa Credo/
Charles River, Les Oncins, France). The animals were housed in a
temperature-controlled room andmaintained on a 12 h day/night
cycle. Food and water were available ad libitum. The experiments
were performed in accordancewith the European Community dir-
ective (86/609/EEC) for the care and use of laboratory animals.
Concentrated viral stocks were thawed on ice and resus-
pended by repeated pipetting. The mice were anaesthetized
using 75 mg/kg ketamine and 10 mg/kg xylazine, administered
intraperitoneally. Lentiviral vectors were stereotaxically injected
into the striatum using a 34-gauge blunt-tip needle linked to a
Hamilton syringe (Hamilton, Reno, NV, USA) by a polyethylene
catheter at the following stereotaxic coordinates: 0.5 mm rostral
to bregma, 2 mm lateral to midline and 3.5 mm from the skull
surface. Each mouse received the vector encoding mHtt alone
in the left striatum and the vectors encoding both mHtt and
AMPKγGOF in the right striatum.
Two hundred nanograms of p24 antigen of each viral vector
was injected at 0.2 μl/min by means of an automatic injector
(Stoelting Co., Wood Dale, USA) and the needle was left in place
for an additional 5 min. The skin was closed using 4-0 Prolene
suture (Ethicon, Johnson and Johnson, Brussels, Belgium).
Histological processing of mice brains
Seven weeks after lentiviral injection, animals received an over-
dose of sodium pentobarbital and were perfused transcardially
with a phosphate-buffered saline solution followed by 4% paraf-
ormaldehyde (Fluka, Sigma, Buchs, Switzerland) and 10% picric
acid ﬁxation. Brains were removed and post-ﬁxed in 4% parafor-
maldehyde and 10% picric acid for 24 h, and then cryoprotected
in 30% sucrose, 0.1  PBS for 48 h. A sledge microtome with a
freezing stage at −25°C (SM2400; Leica Microsystems AG, Glatt-
brugg, Switzerland) was used to cut coronal brain sections of
25 μm thickness. Sections throughout the entire striatum were
collected and stored free-ﬂoating in PBS supplemented with
0.12 μ sodium azide in 96-well plates at 4°C.
Striatal sections from injectedmicewere processed for immu-
nohistochemistry for dopamine and cAMP-regulated phospho-
protein of a molecular mass of 32 kDa (DARPP-32, rabbit
antibody SC11365, Santa Cruz Biotechnology, Santa Cruz, USA,)
and ubiquitin (Ubi, rabbit antibody Z0458, Dakocytomation,
Zug, Switzerland) following the same protocol. Sections were
pre-incubated for 1 h in phenylhydrazin (107 251, Merck KGaA,
Darmstadt, Germany) diluted at 1/1000 in PBS 0.1  at 37°C.
They were rinsed three times in PBS 0.1  then incubated for
1 h in a blocking solution of 10% normal goat serum 0.1% Triton
100-X in PBS 0.1 . Sections were incubated overnight at 4°C in a
solution containing the ﬁrst antibody diluted at 1/1000 (in the
blocking solution for UBI, and in PBS 0.1  5% NGS for DARPP-
32). Theywere thenwashed three times with PBS before applying
the secondary antibody diluted at 1/200 in PBS-1%NGS (biotiny-
lated goat anti-rabbit, BA1000; Vector Laboratories, Inc., CA,
USA) for 1 h at room temperature. The complex was visualized
using the Vectastain ABC kit (PK-6100, Vector Laboratories,
West Grove, USA), with 3,3′-diaminobenzidine tetrahydrochlor-
ide (DAB metal concentrate; Pierce, Rockford, USA) as substrate.
The sections were mounted, dehydrated by soaking twice in
ethanol 100% and toluene solutions, and coverslippedwith Eukitt
(O. Kindler GmbH & CO, Freiburg, Germany).
Quantiﬁcation of DARPP-32 lesions
The loss of DARPP-32 expression was analysed by collecting digi-
tized images of ∼12 sections per animal (150 μm between sec-
tions) with a slide scanner and by quantifying the lesion areas
in square millimetre with an image analysis software (MCID
Core 7.0, InterFocus Imaging, GE Healthcare Niagara, Inc., USA).
Lesion areas in each section were determined as regions poor
in DARPP-32 staining relative to the surrounding tissue. The vol-
umewas then estimatedwith the following formula: volume = d ×
(a1 + a2 + a3 ···), where d is the distance between serial sections
(25 μm), and a1, a2, a3 and on are DARPP-32-depleted areas for
individual sections. The lesion size for each animal is expressed
as the total lesion volume in 8–12 sections. The lesion volume for
each group is expressed as mean ± SEM of individual mouse
values. Statistical analysis was performed using a Wilcoxon
test for paired samples (Statistica 5.1, Statsoft, Inc., USA). The
signiﬁcance level was set at P < 0.05.
Quantiﬁcation of inclusion formation
For estimation of the number of UBI-positive mHtt inclusions, 12
coronal sections of the striatum (separated by 150 μm) were
scanned with a 10× objective using a Zeiss Axioplan2 imaging
microscope equipped with an automated motorized stage and
acquisition system (Mercator Pro V6.50, ExploraNova). The quan-
tiﬁcation of all UBI-positive objects with an apparent cross-sec-
tional area comprised between 1 and 50 μm² was performed as
previously reported (76). The number of UBI-positive aggregates
for each group is expressed as mean ± SEM of individual mouse
values. Statistical analysis was performed using a Wilcoxon
test for paired samples (Statistica 5.1, Statsoft, Inc., USA). The
signiﬁcance level was set at P < 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
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